ETFs Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-19 pm EDT 5-day change 1st Jan Change
857.5 USD +1.01% Intraday chart for Eli Lilly and Company -9.59% +47.10%

ETFs positioned on Eli Lilly and Company

Name Weight AuM 1st Jan change Investor Rating
6.49% 14 M€ +10.53% -
3.30% 92 M€ +0.06% -
3.20% 2 M€ -.--% -
3.19% 9 M€ -.--% -
2.82% 1 M€ +11.94% -
2.82% 3 M€ +7.32% -
2.82% 13 M€ -.--% -
2.71% 5 M€ -72.95% -
2.58% 786 M€ -.--%
2.58% 23 M€ -.--% -
2.56% 284 M€ -.--%
2.18% 2 M€ +14.69% -
1.98% 1,448 M€ -.--% -
1.96% 36 M€ -.--%
1.95% 2 M€ +7.73%
1.86% 9 M€ -4.31% -
1.78% 7 M€ 0.00%
1.70% 1 M€ +0.04%
1.57% 1,848 M€ -.--% -
1.57% 559 M€ -.--% -
1.49% 273 M€ -.--%
1.49% 655 M€ -.--% -
1.49% 1,174 M€ +23.54%
1.46% 414 M€ +17.75% -
1.46% 1,006 M€ -.--% -
1.41% 322 M€ -.--% -
1.41% 29 M€ -.--% -
1.21% 276 M€ +11.40% -
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
857.5 USD
Average target price
909.9 USD
Spread / Average Target
+6.12%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. ETFs Eli Lilly and Company